다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Molecular psychiatry, v.27 no.3, 2022년, pp.1300 - 1309
Huber, Nadine (A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland) , Korhonen, Sonja (A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland) , Hoffmann, Dorit (A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland) , Leskelä, Stina (A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland) , Rostalski, Hannah (A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland) , Remes, Anne M. (Unit of Clinical Neuroscience, Neurology, University of Oulu, P. O. Box 8000, University of Oulu, FI-90014 Oulu, Finland) , Honkakoski, Paavo (School of Pharmacy, University of Eastern Finland, P.O. Box 1627, FI-70210 Kuopio, Finland) , Solje, Eino (Institute of Clinical Medicine—) , Haapasalo, Annakaisa (Neurology, University of Eastern Finland, P.O. Box 1627, FI-70210 Kuopio, Finland)
AI-Helper
Frontotemporal lobar degeneration (FTLD) comprises a heterogenous group of fatal neurodegenerative diseases and, to date, no validated diagnostic or prognostic biomarkers or effective disease-modifying therapies exist for the different clinical or genetic subtypes of FTLD. Current treatment strategi...
1. Rascovsky K Hodges JR Knopman D Mendez MF Kramer JH Neuhaus J Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia A J Neurol 2011 143 2456 77
2. Gorno-Tempini ML Hillis AE Weintraub S Kertesz A Mendez M Cappa SF Classification of primary progressive aphasia and its variants Neurology. 2011 76 1006 14 10.1212/WNL.0b013e31821103e6 21325651
3. Tsai RM Boxer AL Treatment of frontotemporal dementia Curr Treat Options Neurol 2014 16 1 14. 10.1007/s11940-014-0319-0
4. Espay AJ Litvan I Parkinsonism and frontotemporal dementia: the clinical overlap J Mol Neurosci 2011 45 343 9 10.1007/s12031-011-9632-1 21892619
5. Solje E Hartikainen P Valori M Vanninen R Tiihonen J Hakola P The C9ORF72 expansion does not affect the phenotype in Nasu-Hakola disease with the DAP12 mutation Neurobiol Aging 2014 35 1780.e13 1780.e17 10.1016/j.neurobiolaging.2014.01.149
6. Bang J Spina S Miller BL Frontotemporal dementia Lancet. 2015 386 1672 82 10.1016/S0140-6736(15)00461-4 26595641
7. Irwin DJ Cairns NJ Grossman M McMillan CT Lee EB Van Deerlin VM Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine Acta Neuropathol 2015 129 469 91 10.1007/s00401-014-1380-1 25549971
8. Majounie E Renton AE Mok K Dopper EGP Waite A Rollinson S Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study Lancet Neurol 2012 11 323 30 10.1016/S1474-4422(12)70043-1 22406228
9. Renton AE Majounie E Waite A Simón-Sánchez J Rollinson S Gibbs JR A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD Neuron. 2011 72 257 68 10.1016/j.neuron.2011.09.010 21944779
10. DeJesus-Hernandez M Mackenzie IR Boeve BF Boxer AL Baker M Rutherford NJ Expanded GGGGCC hexanucleotide repeat in non-coding region of C9ORF72 causes chromosome 9p-linked frontotemporal dementia and amyotrophic lateral sclerosis Neuron. 2011 72 245 56 10.1016/j.neuron.2011.09.011 21944778
11. Murray ME Kouri N Lin WL Jack CR Dickson DW Vemuri P Clinicopathologic assessment and imaging of tauopathies in neurodegenerative dementias Alzheimer’s Res Ther 2014 6 1 10.1186/alzrt231 24382028
12. Murley AG Rowe JB Neurotransmitter deficits from fronto temporal lobar degeneration Brain 2018 141 1263 85 10.1093/brain/awx327 29373632
13. Pottier C Ravenscroft TA Sanchez-Contreras M Rademakers R Genetics of FTLD: overview and what else we can expect from genetic studies J Neurochem. 2016 138 Suppl 1 32 53 10.1111/jnc.13622 27009575
14. Greaves CV Rohrer JD An update on genetic frontotemporal dementia J Neurol. 2019 266 2075 86 10.1007/s00415-019-09363-4 31119452
15. Haapasalo A Remes AM Genetic and molecular aspects of frontotemporal lobar degeneration Curr Genet Med Rep. 2015 3 8 18 10.1007/s40142-014-0063-5
16. Kaivorinne A-L Bode MK Paavola L Tuominen H Kallio M Renton AE Clinical characteristics of C9ORF72-linked frontotemporal lobar degeneration Dement Geriatr Cogn Dis Extra 2013 3 251 62 10.1159/000351859 24052799
17. Mori K Weng SM Arzberger T May S Rentzsch K Kremmer E The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS Science (80-) 2013 339 1335 8 10.1126/science.1232927
18. Gendron TF Bieniek KF Zhang YJ Jansen-West K Ash PEA Caulfield T Antisense transcripts of the expanded C9ORF72 hexanucleotide repeat form nuclear RNA foci and undergo repeat-associated non-ATG translation in c9FTD/ALS Acta Neuropathol 2013 126 829 44 10.1007/s00401-013-1192-8 24129584
19. Frick P Sellier C Mackenzie IRA Cheng CY Tahraoui-Bories J Martinat C Novel antibodies reveal presynaptic localization of C9orf72 protein and reduced protein levels in C9orf72 mutation carriers Acta Neuropathol Commun 2018 6 72 10.1186/s40478-018-0579-0 30075745
20. Fratta P Poulter M Lashley T Rohrer JD Polke JM Beck J Homozygosity for the C9orf72 GGGGCC repeat expansion in frontotemporal dementia Acta Neuropathol 2013 126 401 9 10.1007/s00401-013-1147-0 23818065
21. O’Rourke JG Bogdanik L Yáñez A Lall D Wolf AJ Muhammad AKMG C9orf72 is required for proper macrophage and microglial function in mice Science (80-) 2016 351 1324 9 10.1126/science.aaf1064
22. Atanasio A Decman V White D Ramos M Ikiz B Lee HC C9orf72 ablation causes immune dysregulation characterized by leukocyte expansion, autoantibody production, and glomerulonephropathy in mice Sci Rep. 2016 6 23204 10.1038/srep23204 26979938
23. Koppers M Blokhuis AM Westeneng HJ Terpstra ML Zundel CAC Vieira De Sá R C9orf72 ablation in mice does not cause motor neuron degeneration or motor deficits Ann Neurol 2015 78 426 38 10.1002/ana.24453 26044557
24. Shi Y Lin S Staats KA Li Y Chang WH Hung ST Haploinsufficiency leads to neurodegeneration in C9ORF72 ALS/FTD human induced motor neurons Nat Med 2018 24 313 25 10.1038/nm.4490 29400714
25. Sellier C Campanari M Julie Corbier C Gaucherot A Kolb‐Cheynel I Oulad‐Abdelghani M Loss of C9ORF72 impairs autophagy and synergizes with polyQ Ataxin‐2 to induce motor neuron dysfunction and cell death EMBO J 2016 35 1276 97 10.15252/embj.201593350 27103069
26. Starr A Sattler R Synaptic dysfunction and altered excitability in C9ORF72 ALS/FTD Brain Res 2018 1693 98 108 10.1016/j.brainres.2018.02.011 29453960
27. Iacoangeli A Tiedge H Translational control at the synapse: role of RNA regulators Trends Biochem Sci 2013 38 47 55 10.1016/j.tibs.2012.11.001 23218750
28. Burguete AS Almeida S Gao F-B Kalb R Akins MR Bonini NM GGGGCC microsatellite RNA is neuritically localized, induces branching defects, and perturbs transport granule function Elife. 2015 4 e08881 10.7554/eLife.08881 26650351
29. Perry S Han Y Das A Dickman D Homeostatic plasticity can be induced and expressed to restore synaptic strength at neuromuscular junctions undergoing ALS-related degeneration Hum Mol Genet 2017 26 4153 67 10.1093/hmg/ddx304 28973139
30. May S Hornburg D Schludi MH Arzberger T Rentzsch K Schwenk BM C9orf72 FTLD/ALS-associated Gly-Ala dipeptide repeat proteins cause neuronal toxicity and Unc119 sequestration Acta Neuropathol 2014 128 485 503 10.1007/s00401-014-1329-4 25120191
31. Jensen BK Schuldi MH McAvoy K Russell KA Boehringer A Curran BM Synaptic dysfunction induced by glycine‐alanine dipeptides in C9orf72‐ ALS / FTD is rescued by SV 2 replenishment. EMBO Mol Med. 2020 12 e10722 10.15252/emmm.201910722 32347002
32. Dafinca R Barbagallo P Farrimond L Candalija A Scaber J Ababneh NA Impairment of mitochondrial calcium buffering links mutations in C9ORF72 and TARDBP in iPS-derived motor neurons from patients with ALS/FTD Stem Cell Rep. 2020 14 892 908 10.1016/j.stemcr.2020.03.023
33. Devlin A-C Burr K Borooah S Foster JD Cleary EM Geti I Human iPSC-derived motoneurons harbouring TARDBP or C9ORF72 ALS mutations are dysfunctional despite maintaining viability Nat Commun 2015 6 1 12.
34. Henley JM Wilkinson KA Synaptic AMPA receptor composition in development, plasticity and disease Nat Rev Neurosci 2016 17 337 50 10.1038/nrn.2016.37 27080385
35. Hideyama T Yamashita T Suzuki T Tsuji S Higuchi M Seeburg PH Induced loss of ADAR2 engenders slow death of motor neurons from Q/R site-unedited GluR2 J Neurosci 2010 30 11917 25 10.1523/JNEUROSCI.2021-10.2010 20826656
36. Donnelly CJ Zhang P-W Pham JT Haeusler AR Heusler AR Mistry NA RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention Neuron 2013 80 415 28 10.1016/j.neuron.2013.10.015 24139042
37. Xu W Xu J C9orf72 dipeptide repeats cause selective neurodegeneration and cell-autonomous excitotoxicity in Drosophila glutamatergic neurons J Neurosci. 2018 38 7741 52 10.1523/JNEUROSCI.0908-18.2018 30037833
38. Perkins EM Burr K Banerjee P Mehta AR Dando O Selvaraj BT Altered network properties in C9ORF72 repeat expansion cortical neurons are due to synaptic dysfunction Mol Neurodegener 2021 16 13 10.1186/s13024-021-00433-8 33663561
39. Chen-Plotkin AS Martinez-Lage M Sleiman PMA Hu W Greene R Wood EMC Genetic and clinical features of progranulin-associated frontotemporal lobar degeneration Arch Neurol 2011 68 488 97 10.1001/archneurol.2011.53 21482928
40. Eriksen JL Mackenzie IRA Progranulin: normal function and role in neurodegeneration J Neurochem 2008 104 287 97 17953663
41. Petkau TL Neal SJ Milnerwood A Mew A Hill AM Orban P Synaptic dysfunction in progranulin-deficient mice Neurobiol Dis 2012 45 711 22 10.1016/j.nbd.2011.10.016 22062772
42. Longhena F Zaltieri M Grigoletto J Faustini G La Via L Ghidoni R Depletion of progranulin reduces GluN2B-containing NMDA receptor density, tau phosphorylation, and dendritic arborization in mouse primary cortical neurons J Pharm Exp Ther 2017 363 164 75 10.1124/jpet.117.242164
43. Huang M Modeste E Dammer E Merino P Taylor G Duong DM Network analysis of the progranulin-deficient mouse brain proteome reveals pathogenic mechanisms shared in human frontotemporal dementia caused by GRN mutations Acta Neuropathol Commun 2020 8 163 10.1186/s40478-020-01037-x 33028409
44. Lui H Zhang J Makinson SR Cahill MK Kelley KW Huang HY Progranulin deficiency promotes circuit-specific synaptic pruning by microglia via complement activation Cell. 2016 165 921 35 10.1016/j.cell.2016.04.001 27114033
45. Tapia L Milnerwood A Guo A Mills F Yoshida E Vasuta C Progranulin deficiency decreases gross neural connectivity but enhances transmission at individual synapses J Neurosci 2011 31 11126 32 10.1523/JNEUROSCI.6244-10.2011 21813674
46. Foster NL Wilhelmsen K Sima AAF Jones MZ D’Amato CJ Gilman S Frontotemporal dementia and parkinsonism linked to chromosome 17: a consensus conference Ann Neurol. 1997 41 706 15 10.1002/ana.410410606 9189031
47. Buée L Delacourte A Comparative biochemistry of tau in progressive supranuclear palsy, corticobasal degeneration, FTDP-17 and Pick’s disease Brain Pathol 1999 9 681 93 10.1111/j.1750-3639.1999.tb00550.x 10517507
48. Dickson DW Kouri N Murray ME Josephs KA Neuropathology of frontotemporal lobar degeneration-tau (FTLD-tau) J Mol Neurosci 2011 45 384 9 10.1007/s12031-011-9589-0 21720721
49. Avila J Lucas JJ Pérez M Hernández F Role of tau protein in both physiological and pathological conditions Physiol Rev 2004 84 361 84 10.1152/physrev.00024.2003 15044677
50. Dixit R Ross JL Goldman YE Holzbaur ELF Differential regulation of dynein and kinesin motor proteins by tau Science (80-) 2008 319 1086 9 10.1126/science.1152993
51. Fulga TA Elson-Schwab I Khurana V Steinhilb ML Spires TL Hyman BT Abnormal bundling and accumulation of F-actin mediates tau-induced neuronal degeneration in vivo Nat Cell Biol 2007 9 139 48 10.1038/ncb1528 17187063
52. Yoshiyama Y Higuchi M Zhang B Huang SM Iwata N Saido TCC Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model Neuron 2007 53 337 51 10.1016/j.neuron.2007.01.010 17270732
53. Hoover BR Reed MN Su J Penrod RD Kotilinek LA Grant MK Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration Neuron. 2010 68 1067 81 10.1016/j.neuron.2010.11.030 21172610
54. Vogel JW Iturria-Medina Y Strandberg OT Smith R Levitis E Evans AC Spread of pathological tau proteins through communicating neurons in human Alzheimer’s disease Nat Commun 2020 11 1 15. 10.1038/s41467-019-13993-7 31911652
55. Mudher A Colin M Dujardin S Medina M Dewachter I Alavi Naini SM What is the evidence that tau pathology spreads through prion-like propagation? Acta Neuropathol Commun 2017 5 1 20. 10.1186/s40478-016-0408-2 28057070
56. Kim E-J Hwang J-HL Gaus SE Nana AL Deng J Brown JA Evidence of corticofugal tau spreading in patients with frontotemporal dementia Acta Neuropathol 2020 139 27 10.1007/s00401-019-02075-z 31542807
57. Benussi A Di Lorenzo F Dell’Era V Cosseddu M Alberici A Caratozzolo S Transcranial magnetic stimulation distinguishes Alzheimer disease from frontotemporal dementia Neurology. 2017 89 665 72 10.1212/WNL.0000000000004232 28747446
58. Niciu MJ Kelmendi B Sanacora G Overview of glutamatergic neurotransmission in the nervous system Pharm Biochem Behav 2012 100 656 64 10.1016/j.pbb.2011.08.008
59. Benussi A Alberici A Buratti E Ghidoni R Gardoni F Di Luca M Toward a glutamate hypothesis of frontotemporal dementia Front Neurosci 2019 13 1 9 10.3389/fnins.2019.00304 30740042
60. Ferrer I Neurons and their dendrites in frontotemporal dementia Dement Geriatr Cogn Disord 1999 10 55 60 10.1159/000051214 10436342
61. Padovani A Benussi A Cantoni V Dell’Era V Cotelli MS Caratozzolo S Diagnosis of mild cognitive impairment due to Alzheimer’s disease with transcranial magnetic stimulation J Alzheimer’s Dis. 2018 65 221 30 10.3233/JAD-180293 30010131
62. Borroni B Stanic J Verpelli C Mellone M Bonomi E Alberici A Anti-AMPA GluA3 antibodies in Frontotemporal dementia: a new molecular target Sci Rep. 2017 7 1 10. 10.1038/s41598-017-06117-y 28127051
63. Adamczyk A Mejias R Takamiya K Yocum J Krasnova IN Calderon J GluA3-deficiency in mice is associated with increased social and aggressive behavior and elevated dopamine in striatum Behav Brain Res 2012 229 265 72 10.1016/j.bbr.2012.01.007 22285418
64. Wu C Sun D GABA receptors in brain development, function, and injury Metab Brain Dis 2015 30 367 79 10.1007/s11011-014-9560-1 24820774
65. Paredes RG Ågmo A GABA and behavior: the role of receptor subtypes Neurosci Biobehav Rev 1992 16 145 70 10.1016/S0149-7634(05)80177-0 1321392
66. Klein MO Battagello DS Cardoso AR Hauser DN Bittencourt JC Correa RG Dopamine: functions, signaling, and association with neurological diseases Cell Mol Neurobiol 2019 39 31 59 10.1007/s10571-018-0632-3 30446950
67. Rinne JO Laine M Kaasinen V Norvasuo-Heilä MK Någren K Helenius H Striatal dopamine transporter and extrapyramidal symptoms in frontotemporal dementia Neurology. 2002 58 1489 93 10.1212/WNL.58.10.1489 12034784
68. Siuda J Fujioka S Wszolek ZK Parkinsonian syndrome in familial frontotemporal dementia Park Relat Disord 2014 20 957 64 10.1016/j.parkreldis.2014.06.004
69. Park HK Chung SJ New perspective on parkinsonism in frontotemporal lobar degeneration J Mov Disord. 2013 6 1 8 10.14802/jmd.13001 24868417
70. Broft A Shingleton R Kaufman J Liu F Kumar D Slifstein M Striatal dopamine in bulimia nervosa: a PET imaging study Int J Eat Disord 2012 45 648 56 10.1002/eat.20984 22331810
71. Ahmed RM Irish M Kam J Van Keizerswaard J Bartley L Samaras K Quantifying the eating abnormalities in frontotemporal dementia JAMA Neurol 2014 71 1540 6 10.1001/jamaneurol.2014.1931 25329012
72. Ciranna L Serotonin as a modulator of glutamate- and GABA-mediated neurotransmission: implications in physiological functions and in pathology Curr Neuropharmacol 2006 4 101 14 10.2174/157015906776359540 18615128
73. Donovan MH Tecott LH Serotonin and the regulation of mammalian energy balance Front Neurosci 2013 7 36 10.3389/fnins.2013.00036 23543912
74. Maillet A Krack P Lhommée E Météreau E Klinger H Favre E The prominent role of serotonergic degeneration in apathy, anxiety and depression in de novo Parkinson’s disease Brain. 2016 139 2486 502 10.1093/brain/aww162 27538418
75. Bowen DM Procter AW Mann DMA Snowden JS Esiri MM Neary D Imbalance of a serotonergic system in frontotemporal dementia: Implication for pharmacotherapy Psychopharmacol (Berl) 2008 196 603 10 10.1007/s00213-007-0992-8
76. Vermeiren Y Janssens J Aerts T Martin JJ Sieben A Van Dam D Brain serotonergic and noradrenergic deficiencies in behavioral variant frontotemporal dementia compared to early-onset Alzheimer’s disease J Alzheimer’s Dis. 2016 53 1079 96 10.3233/JAD-160320 27314528
77. Yang Y Schmitt HP Frontotemporal dementia: evidence for impairment of ascending serotoninergic but not noradrenergic innervation. Immunocytochemical and quantitative study using a graph method Acta Neuropathol 2001 101 256 70 10.1007/s004010000293 11307626
78. Schwarz LA Luo L Organization of the locus coeruleus-norepinephrine system Curr Biol 2015 25 R1051 R1056. 10.1016/j.cub.2015.09.039 26528750
79. Xing B Li YC Gao WJ Norepinephrine versus dopamine and their interaction in modulating synaptic function in the prefrontal cortex Brain Res 2016 1641 217 33 10.1016/j.brainres.2016.01.005 26790349
80. Gannon M Che P Chen Y Jiao K Roberson ED Wang Q Noradrenergic dysfunction in Alzheimer’s disease Front Neurosci 2015 9 220 10.3389/fnins.2015.00220 26136654
81. Chandler DJ Gao WJ Waterhouse BD Heterogeneous organization of the locus coeruleus projections to prefrontal and motor cortices Proc Natl Acad Sci USA 2014 111 6816 21 10.1073/pnas.1320827111 24753596
82. Picciotto MR Acetylcholine as a neuromodulator Neuron. 2013 76 116 29 10.1016/j.neuron.2012.08.036
83. Teipel S Raiser T Riedl L Riederer I Schroeter ML Bisenius S Atrophy and structural covariance of the cholinergic basal forebrain in primary progressive aphasia Cortex. 2016 83 124 35 10.1016/j.cortex.2016.07.004 27509365
84. Nelissen N Bormans G Vandenberghe R Dupont P Vandenberghe R Vandenberghe R Cholinergic depletion and basal forebrain volume in primary progressive aphasia NeuroImage Clin 2017 13 271 9 10.1016/j.nicl.2016.11.027 28018854
85. López-Álvarez J Sevilla-Llewellyn-Jones J Agüera-Ortiz L Anticholinergic drugs in geriatric psychopharmacology Front Neurosci 2019 13 1309 10.3389/fnins.2019.01309 31866817
86. Kertesz A Morlog D Light M Blair M Davidson W Jesso S Galantamine in frontotemporal dementia and primary progressive aphasia Dement Geriatr Cogn Disord 2008 25 178 85 10.1159/000113034 18196898
87. Smith SM Fox PT Miller KL Glahn DC Fox PM Mackay CE Correspondence of the brain’s functional architecture during activation and rest Proc Natl Acad Sci USA 2009 106 13040 5 10.1073/pnas.0905267106 19620724
88. Lee SE Khazenzon AM Trujillo AJ Guo CC Yokoyama JS Sha SJ Altered network connectivity in frontotemporal dementia with C9orf72 hexanucleotide repeat expansion Brain. 2014 137 3047 60 10.1093/brain/awu248 25273996
89. Dopper EGP Rombouts SARB Jiskoot LC Heijer T Den De Graaf JRA De Koning I Structural and functional brain connectivity in presymptomatic familial frontotemporal dementia Neurology 2014 83 e19 26 10.1212/WNL.0000000000000583 25002573
90. Seeley WW Crawford RK Zhou J Miller BL Greicius MD Neurodegenerative diseases target large-scale human brain networks Neuron. 2009 62 42 10.1016/j.neuron.2009.03.024 19376066
91. Filippi M Agosta F Scola E Canu E Magnani G Marcone A Functional network connectivity in the behavioral variant of frontotemporal dementia Cortex. 2013 49 2389 401 10.1016/j.cortex.2012.09.017 23164495
92. Farb NAS Grady CL Strother S Tang-Wai DF Masellis M Black S Abnormal network connectivity in frontotemporal dementia: evidence for prefrontal isolation Cortex. 2013 49 1856 73 10.1016/j.cortex.2012.09.008 23092697
93. Whitwell JL Josephs KA Avula R Tosakulwong N Weigand SD Senjem ML Altered functional connectivity in asymptomatic MAPT subjects A comparison to bvFTD Neurology. 2011 77 866 74 10.1212/WNL.0b013e31822c61f2 21849646
94. Zhou J Greicius MD Gennatas ED Growdon ME Jang JY Rabinovici GD Divergent network connectivity changes in behavioural variant frontotemporal dementia and Alzheimer’s disease Brain. 2010 133 1352 67 10.1093/brain/awq075 20410145
95. Sellami L Bocchetta M Masellis M Cash DM Dick KM Van Swieten J Distinct neuroanatomical correlates of neuropsychiatric symptoms in the three main forms of genetic frontotemporal dementia in the GENFI Cohort J Alzheimer’s Dis. 2018 65 147 63. 30010122
96. Premi E Cauda F Costa T Diano M Gazzina S Gualeni V Looking for neuroimaging markers in frontotemporal lobar degeneration clinical trials: a multi-voxel pattern analysis study in granulin disease J Alzheimer’s Dis. 2016 51 249 62 10.3233/JAD-150340 26836150
97. Lacomblez L Bensimon G Leigh PN Guillet P Meininger V Dose-ranging study of riluzole in amyotrophic lateral sclerosis Lancet. 1996 347 1425 31 10.1016/S0140-6736(96)91680-3 8676624
98. Bensimon G Lacomblez L Meininger V A controlled trial of riluzole in amyotrophic lateral sclerosis N. Engl J Med. 1994 330 585 91 10.1056/NEJM199403033300901 8302340
99. Casarotto PC Girych M Fred SM Kovaleva V Moliner R Enkavi G Antidepressant drugs act by directly binding to TRKB neurotrophin receptors Cell. 2021 184 1299 313.e19 10.1016/j.cell.2021.01.034 33606976
100. Anneser JMH Jox RJ Borasio GD Inappropriate sexual behaviour in a case of ALS and FTD: Successful treatment with sertraline Amyotroph Lateral Scler 2007 8 189 90 10.1080/17482960601073543 17538783
101. Hughes LE Rittman T Regenthal R Robbins TW Rowe JB Improving response inhibition systems in frontotemporal dementia with citalopram Brain. 2015 138 1961 75 10.1093/brain/awv133 26001387
102. Deakin JB Rahman S Nestor PJ Hodges JR Sahakian BJ Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial Psychopharmacol (Berl) 2004 172 400 8 10.1007/s00213-003-1686-5
103. Lebert F Stekke W Hasenbroekx C Pasquier F Frontotemporal dementia: A randomised, controlled trial with trazodone Dement Geriatr Cogn Disord 2004 17 355 9 10.1159/000077171 15178953
104. Chow TW Mendez MF Goals in symptomatic pharmacologic management of frontotemporal lobar degeneration Am J Alzheimers Dis Other Demen. 2002 17 267 72 10.1177/153331750201700504 12392261
105. Huey ED Section CN Garcia C Grant W Clinical M Wassermann EM Stimulant treatment of frontotemporal dementia in 8 patients J Clin Psychiatry. 2008 69 1981 2 10.4088/JCP.v69n1219a 19203481
106. Moretti R Torre P Antonello RM Cazzato G Griggio S Bava A Olanzapine as a treatment of neuropsychiatric disorders of Alzheimer’s disease and other dementias: A 24-month follow-up of 68 patients Am J Alzheimers Dis Other Demen 2003 18 205 14 10.1177/153331750301800410 12955785
107. Steinberg M Lyketsos CG Atypical antipsychotic use in patients with dementia: managing safety concern Am J Psychiatry. 2012 169 900 6 10.1176/appi.ajp.2012.12030342 22952071
108. Boeve BF Boylan KB Graff-Radford NR Dejesus-Hernandez M Knopman DS Pedraza O Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72 Brain. 2012 135 765 83 10.1093/brain/aws004 22366793
109. Kerrsens CJ Pijnenburg YAL Vulnerability to neuroleptic side effects in frontotemporal dementia Eur J Neurol 2008 15 111 2 10.1111/j.1468-1331.2007.02035.x 18217880
110. Bialer M Why are antiepileptic drugs used for nonepileptic conditions? Epilepsia. 2012 53 26 33 10.1111/j.1528-1167.2012.03712.x 23153207
111. Dafinca R Scaber J Ababneh N Lalic T Weir G Christian H C9orf72 hexanucleotide expansions are associated with altered endoplasmic reticulum calcium homeostasis and stress granule formation in induced pluripotent stem cell-derived neurons from patients with amyotrophic lateral sclerosis and frontotemporal demen Stem Cells 2016 34 2063 78 10.1002/stem.2388 27097283
112. Poetter CE Stewart JT Treatment of indiscriminate, inappropriate sexual behavior in frontotemporal dementia with carbamazepine J Clin Psychopharmacol. 2012 32 137 8 10.1097/JCP.0b013e31823f91b9 22217950
113. Gupta S Ivfesand PS Frank BL Lockwood KL Keller PL Topiramate in bipolar and schizoaffective disorders: Weight loss and efficacy Prim Care Companion J Clin Psychiatry. 2000 2 96 100 10.4088/PCC.v02n0304 15014655
114. Minton GC Miller AD Bookstaver PB Love BL Topiramate: safety and efficacy of its use in the prevention and treatment of migraine J Cent Nerv Syst Dis. 2011 3 JCNSD.S4365 10.4137/JCNSD.S4365
115. Limanaqi F Biagioni F Ryskalin L Busceti CL Fornai F Molecular mechanisms linking ALS/FTD and psychiatric disorders, the potential effects of lithium Front Cell Neurosci 2019 13 1 10. 10.3389/fncel.2019.00450 30723396
116. Hampel H Mesulam MM Cuello AC Farlow MR Giacobini E Grossberg GT The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease Brain. 2018 141 1917 33 10.1093/brain/awy132 29850777
117. Moretti R Torre P Antonello RM Cattaruzza T Cazzato G Bava A Rivastigmine in frontotemporal dementia: an open-label study Drugs Aging 2004 21 931 7 10.2165/00002512-200421140-00003 15554751
118. Mendez MF Shapira JS McMurtray A Licht E Preliminary findings? Behavioral worsening on donepezil in patients with frontotemporal dementia Am J Geriatr Psychiatry. 2007 15 84 87 10.1097/01.JGP.0000231744.69631.33 17194818
119. Parsons CG Stöffler A Danysz W Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system—too little activation is bad, too much is even worse Neuropharmacology. 2007 53 699 723 10.1016/j.neuropharm.2007.07.013 17904591
120. Diehl‐Schmid J Förstl H Perneczky R Pohl C Kurz A A 6‐month, open‐label study of memantine in patients with frontotemporal dementia Int J Geriatr Psychiatry. 2008 23 754 9 10.1002/gps.1973 18213609
121. Boxer AL Lipton AM Womack K Neuhaus J Pavlic D Gandhi A An open label study of memantine treatment in three subtypes of frontotemporal lobar degeneration Alzheimer Disord Assoc Disord 2010 23 211 7 10.1097/WAD.0b013e318197852f
122. Boxer AL Knopman DS Kaufer DI Grossman M Onyike C Graf-Radford N Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial Lancet Neurol 2013 12 149 56 10.1016/S1474-4422(12)70320-4 23290598
123. Rahman S Robbins TW Hodges JR Mehta MA Nestor PJ Clark L Methylphenidate (‘Ritalin’) can ameliorate abnormal risk-taking behavior in the frontal variant of frontotemporal dementia Neuropsychopharmacology. 2006 31 651 8 10.1038/sj.npp.1300886 16160709
124. Moretti R Torre P Antonello RM Cazzato G Bava A Effects of selegiline on fronto-temporal dementia: A neuropsychological evaluation Int J Geriatr Psychiatry. 2002 17 391 2 10.1002/gps.602 11994896
125. Marken PA Stuart Munro J Selecting a selective serotonin reuptake inhibitor: Clinically important distinguishing features Prim Care Companion J Clin Psychiatry 2000 2 205 10 10.4088/PCC.v02n0602 15014630
126. Su Z Zhang Y Gendron TF Bauer PO Chew J Yang WY Discovery of a biomarker and lead small molecules to target r(GGGGCC)-associated defects in c9FTD/ALS Neuron 2014 83 1043 50 10.1016/j.neuron.2014.07.041 25132468
127. Brown DG, Shorter J, Wobst HJ Emerging small-molecule therapeutic approaches for amyotrophic lateral sclerosis and frontotemporal dementia. Bioorganic Med Chem Lett. 2020;30:126942.
128. Cappella M, Ciotti C, Cohen-tannoudji M, Biferi MG Gene therapy for ALS — A perspective. Int J Mol Sci. 2019;20:4388.
129. Giunta M Solje E Gardoni F Borroni B Benussi A Experimental disease-modifying agents for frontotemporal lobar degeneration J Exp Pharmacol 2021 13 359 76 10.2147/JEP.S262352 33790662
130. Reba RC Gibson R Molchan S Sunderland T Coppola R Jones DW The distribution of cerebral muscarinic acetylcholine receptors in vivo in patients with dementia: a controlled study with 123iqnb and single photon emission computed tomography Arch Neurol 1991 48 169 76 10.1001/archneur.1991.00530140061018 1993008
131. Procter AW Qurne M Francis PT Neurochemical features of frontotemporal dementia Dement Geriatr Cogn Disord 1999 10 80 84 10.1159/000051219 10436347
132. Herrmann N Black SE Chow T Cappell J Tang-Wai DF Lanctôt KL Serotonergic function and treatment of behavioral and psychological symptoms of frontotemporal dementia Am J Geriatr Psychiatry. 2012 20 789 97 10.1097/JGP.0b013e31823033f3 21878805
133. Wainger BJ Kiskinis E Mellin C Wiskow O Steve SW Berry JD Intrinsic membrane hyperexcitability of ALS patient-derived motor neurons Cell Rep. 2014 7 1 11 10.1016/j.celrep.2014.03.019 24703839
134. Singam C Walterfang M Mocellin R Evans A Velakoulis D Topiramate for abnormal eating behaviour in frontotemporal dementia Behav Neurol 2013 27 285 6 10.1155/2013/547853 23548883
135. Swanberg MM Memantine for behavioral disturbances in frontotemporal dementia: a case series Alzheimer Dis Assoc Disord 2007 21 164 6 10.1097/WAD.0b013e318047df5d 17545743
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
저자가 APC(Article Processing Charge)를 지불한 논문에 한하여 자유로운 이용이 가능한, hybrid 저널에 출판된 논문
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.